JP2017530982A - 神経刺激性化合物およびその使用方法 - Google Patents
神経刺激性化合物およびその使用方法 Download PDFInfo
- Publication number
- JP2017530982A JP2017530982A JP2017518329A JP2017518329A JP2017530982A JP 2017530982 A JP2017530982 A JP 2017530982A JP 2017518329 A JP2017518329 A JP 2017518329A JP 2017518329 A JP2017518329 A JP 2017518329A JP 2017530982 A JP2017530982 A JP 2017530982A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- certain embodiments
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC(CC(*)N)C(CCC(C)(*)C#*)[C@@](CC1)CC[C@](CC2)C1C(CC1)C2[C@]2(*)C1C[C@@](*CC(F)(F)F)CC2 Chemical compound CC(CC(*)N)C(CCC(C)(*)C#*)[C@@](CC1)CC[C@](CC2)C1C(CC1)C2[C@]2(*)C1C[C@@](*CC(F)(F)F)CC2 0.000 description 10
- VCKGFMZZUCDSCY-KQGOFIGCSA-N CC(C)C(C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)O Chemical compound CC(C)C(C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)O VCKGFMZZUCDSCY-KQGOFIGCSA-N 0.000 description 1
- VCKGFMZZUCDSCY-FHUXGQEASA-N CC(C)[C@@](C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)O Chemical compound CC(C)[C@@](C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)O VCKGFMZZUCDSCY-FHUXGQEASA-N 0.000 description 1
- KFNMXUHNHJZIRK-DPXZGAGYSA-N CC(C)[C@@](C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)O Chemical compound CC(C)[C@@](C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)O KFNMXUHNHJZIRK-DPXZGAGYSA-N 0.000 description 1
- VCKGFMZZUCDSCY-CNDFOAKRSA-N CC(C)[C@](C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)O Chemical compound CC(C)[C@](C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)O VCKGFMZZUCDSCY-CNDFOAKRSA-N 0.000 description 1
- KFNMXUHNHJZIRK-KMPIVKRFSA-N CC(C)[C@](C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)O Chemical compound CC(C)[C@](C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)O KFNMXUHNHJZIRK-KMPIVKRFSA-N 0.000 description 1
- HGGRUCBHJRFHLG-RTQKIXDOSA-N CC(CCC(C)(C)N)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CCC(C)(C)N)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 HGGRUCBHJRFHLG-RTQKIXDOSA-N 0.000 description 1
- KAQAQNAZFYCCDI-DOJZEQSCSA-N CC(CCC(C)(C)NC)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CCC(C)(C)NC)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@H](C2)O)C2=CC1 KAQAQNAZFYCCDI-DOJZEQSCSA-N 0.000 description 1
- MFUUUYUCTJBOML-HHLKQVQWSA-N CC(CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)NC)C2=CC1 Chemical compound CC(CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)NC)C2=CC1 MFUUUYUCTJBOML-HHLKQVQWSA-N 0.000 description 1
- QUHRVBCBSGYBBE-VMNDBUHGSA-N CC(CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@H](C2)NC(CCCC(O)=O)=O)C2=CC1 Chemical compound CC(CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@H](C2)NC(CCCC(O)=O)=O)C2=CC1 QUHRVBCBSGYBBE-VMNDBUHGSA-N 0.000 description 1
- USOOWRCOYYNZPU-CKYNZBCFSA-N CC(CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@H](C2)O)C2=CC1 USOOWRCOYYNZPU-CKYNZBCFSA-N 0.000 description 1
- SJAMKYATLBQQET-JMNNKSSHSA-N CC(CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](CF)(C2)O)C2=CC1 Chemical compound CC(CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](CF)(C2)O)C2=CC1 SJAMKYATLBQQET-JMNNKSSHSA-N 0.000 description 1
- YIKOZCZTTYGXNE-OAXNQQOCSA-N CC(CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](COC)(C2)O)C2=CC1 Chemical compound CC(CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](COC)(C2)O)C2=CC1 YIKOZCZTTYGXNE-OAXNQQOCSA-N 0.000 description 1
- LYTWKKNLBOQGLV-RTQKIXDOSA-N CC(CCC(C)(C)S)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CCC(C)(C)S)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 LYTWKKNLBOQGLV-RTQKIXDOSA-N 0.000 description 1
- XMNNDQZLWPKUIU-AWUZTYEYSA-N CCC(C[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)(F)F Chemical compound CCC(C[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)(F)F XMNNDQZLWPKUIU-AWUZTYEYSA-N 0.000 description 1
- DSWZTQNRIMMWOZ-LGQWAPFCSA-N CC[C@@]1(CC2=CCC(C(CC3)[C@](C)(CC4)[C@H]3[C@H](C)CCC(C)(C)O)C4[C@@]2(C)CC1)O Chemical compound CC[C@@]1(CC2=CCC(C(CC3)[C@](C)(CC4)[C@H]3[C@H](C)CCC(C)(C)O)C4[C@@]2(C)CC1)O DSWZTQNRIMMWOZ-LGQWAPFCSA-N 0.000 description 1
- SOUHEILYARIBRI-DJRRQLMKSA-N CC[C@H](CCC(CCC1)C2C1[C@@H](CC[C@@H](C1)S)C1=CC2)C(C)CCC(C)(C)O Chemical compound CC[C@H](CCC(CCC1)C2C1[C@@H](CC[C@@H](C1)S)C1=CC2)C(C)CCC(C)(C)O SOUHEILYARIBRI-DJRRQLMKSA-N 0.000 description 1
- DZEXDMMVZMPZPX-BGZSYFAVSA-N C[C@H](CC(C(C)(C)O)(F)F)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CC(C(C)(C)O)(F)F)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 DZEXDMMVZMPZPX-BGZSYFAVSA-N 0.000 description 1
- ZCKNSKLMRTZMIB-VHFVPTDGSA-N C[C@H](CC([C@H](C)O)(F)F)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O Chemical compound C[C@H](CC([C@H](C)O)(F)F)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O ZCKNSKLMRTZMIB-VHFVPTDGSA-N 0.000 description 1
- KEXGJVHTVFVZAK-PCNQZJBLSA-N C[C@H](CCC(C)(C)N)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@H](C2)O)C2=CC1 Chemical compound C[C@H](CCC(C)(C)N)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@H](C2)O)C2=CC1 KEXGJVHTVFVZAK-PCNQZJBLSA-N 0.000 description 1
- FEGRCLVMYKTTDC-MOTQOULQSA-N C[C@H](CCC(C)(C1CC1)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CCC(C)(C1CC1)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 FEGRCLVMYKTTDC-MOTQOULQSA-N 0.000 description 1
- FEGRCLVMYKTTDC-FBIXSMBYSA-N C[C@H](CC[C@@](C)(C1CC1)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CC[C@@](C)(C1CC1)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 FEGRCLVMYKTTDC-FBIXSMBYSA-N 0.000 description 1
- FEGRCLVMYKTTDC-TUNIIZQNSA-N C[C@H](CC[C@](C)(C1CC1)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CC[C@](C)(C1CC1)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 FEGRCLVMYKTTDC-TUNIIZQNSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060932P | 2014-10-07 | 2014-10-07 | |
| US62/060,932 | 2014-10-07 | ||
| PCT/US2015/054551 WO2016057713A1 (en) | 2014-10-07 | 2015-10-07 | Neuroactive compounds and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020149725A Division JP2020196759A (ja) | 2014-10-07 | 2020-09-07 | 神経刺激性化合物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530982A true JP2017530982A (ja) | 2017-10-19 |
| JP2017530982A5 JP2017530982A5 (enExample) | 2018-11-15 |
Family
ID=55653736
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518329A Withdrawn JP2017530982A (ja) | 2014-10-07 | 2015-10-07 | 神経刺激性化合物およびその使用方法 |
| JP2020149725A Withdrawn JP2020196759A (ja) | 2014-10-07 | 2020-09-07 | 神経刺激性化合物およびその使用方法 |
| JP2022000454A Pending JP2022033285A (ja) | 2014-10-07 | 2022-01-05 | 神経刺激性化合物およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020149725A Withdrawn JP2020196759A (ja) | 2014-10-07 | 2020-09-07 | 神経刺激性化合物およびその使用方法 |
| JP2022000454A Pending JP2022033285A (ja) | 2014-10-07 | 2022-01-05 | 神経刺激性化合物およびその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20170304321A1 (enExample) |
| EP (1) | EP3204011A4 (enExample) |
| JP (3) | JP2017530982A (enExample) |
| KR (1) | KR20170065637A (enExample) |
| CN (2) | CN107405352A (enExample) |
| AU (2) | AU2015330906A1 (enExample) |
| BR (1) | BR112017007053A2 (enExample) |
| CA (1) | CA2963938C (enExample) |
| IL (2) | IL292465B2 (enExample) |
| MX (2) | MX388694B (enExample) |
| MY (1) | MY202135A (enExample) |
| PE (1) | PE20170907A1 (enExample) |
| PH (1) | PH12017500639A1 (enExample) |
| RU (1) | RU2764702C2 (enExample) |
| SG (2) | SG11201702799UA (enExample) |
| WO (1) | WO2016057713A1 (enExample) |
| ZA (1) | ZA201702545B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013036835A1 (en) | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| RS67266B1 (sr) | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| ES2852054T3 (es) | 2013-03-15 | 2021-09-10 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SMT202200094T1 (it) | 2013-12-24 | 2022-05-12 | Univ Virginia Commonwealth | Uso di solfati di colesterolo ossigenati (ocs) per il trattamento dell’insufficienza epatica acuta |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| BR112018000129B1 (pt) | 2015-07-06 | 2024-01-09 | Sage Therapeutics, Inc | Compostos oxiesteróis, seus usos e composição farmacêutica |
| JP6882996B2 (ja) * | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| SMT202100476T1 (it) | 2015-07-06 | 2021-09-14 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| SI3436022T1 (sl) | 2016-04-01 | 2022-08-31 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| WO2018026781A1 (en) * | 2016-08-02 | 2018-02-08 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| MX392270B (es) | 2016-09-30 | 2025-03-24 | Sage Therapeutics Inc | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. |
| EP4105223B1 (en) | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN110267966B (zh) * | 2016-10-18 | 2022-07-08 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| EP3335730A1 (en) * | 2016-12-15 | 2018-06-20 | Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) | Compounds for treating x-linked adrenoleukodystrophy |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014160441A1 (en) * | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO2006037016A2 (en) * | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| GB0712494D0 (en) * | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| US20110118353A1 (en) * | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| CA2722776A1 (en) * | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) * | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010088414A2 (en) * | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| WO2011028794A2 (en) * | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| WO2013036835A1 (en) * | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP2841067A4 (en) * | 2012-04-25 | 2016-04-13 | Univ California | MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME |
| WO2014025942A1 (en) * | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| AU2014212487C1 (en) * | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| RS67266B1 (sr) | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| WO2015195967A1 (en) * | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2016007762A1 (en) * | 2014-07-09 | 2016-01-14 | Duke University | Compositions and methods for the repair of myelin |
| JP6882996B2 (ja) * | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
-
2015
- 2015-10-07 US US15/517,886 patent/US20170304321A1/en not_active Abandoned
- 2015-10-07 MX MX2017004684A patent/MX388694B/es unknown
- 2015-10-07 CA CA2963938A patent/CA2963938C/en active Active
- 2015-10-07 PE PE2017000579A patent/PE20170907A1/es unknown
- 2015-10-07 KR KR1020177012221A patent/KR20170065637A/ko not_active Ceased
- 2015-10-07 JP JP2017518329A patent/JP2017530982A/ja not_active Withdrawn
- 2015-10-07 CN CN201580063540.7A patent/CN107405352A/zh active Pending
- 2015-10-07 CN CN202011059273.5A patent/CN112121171A/zh active Pending
- 2015-10-07 EP EP15849514.3A patent/EP3204011A4/en active Pending
- 2015-10-07 MY MYPI2017000507A patent/MY202135A/en unknown
- 2015-10-07 AU AU2015330906A patent/AU2015330906A1/en not_active Abandoned
- 2015-10-07 WO PCT/US2015/054551 patent/WO2016057713A1/en not_active Ceased
- 2015-10-07 IL IL292465A patent/IL292465B2/en unknown
- 2015-10-07 BR BR112017007053A patent/BR112017007053A2/pt not_active Application Discontinuation
- 2015-10-07 SG SG11201702799UA patent/SG11201702799UA/en unknown
- 2015-10-07 SG SG10202011773UA patent/SG10202011773UA/en unknown
- 2015-10-07 RU RU2017115849A patent/RU2764702C2/ru active
-
2017
- 2017-04-02 IL IL251505A patent/IL251505B/en unknown
- 2017-04-06 PH PH12017500639A patent/PH12017500639A1/en unknown
- 2017-04-07 MX MX2021011939A patent/MX2021011939A/es unknown
- 2017-04-10 ZA ZA2017/02545A patent/ZA201702545B/en unknown
-
2020
- 2020-09-07 JP JP2020149725A patent/JP2020196759A/ja not_active Withdrawn
-
2021
- 2021-02-04 AU AU2021200721A patent/AU2021200721B2/en active Active
-
2022
- 2022-01-05 JP JP2022000454A patent/JP2022033285A/ja active Pending
- 2022-09-19 US US17/947,844 patent/US20230218638A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014160441A1 (en) * | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| BIOCHEMICAL PHARMACOLOGY, vol. 86, JPN6020008539, 2013, pages 43 - 55, ISSN: 0004227426 * |
| JOURNAL OF LIPID RESEARCH, vol. 42, JPN6020008538, 2001, pages 366 - 371, ISSN: 0004227425 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530982A (ja) | 神経刺激性化合物およびその使用方法 | |
| JP7602513B2 (ja) | オキシステロールおよびそれらの使用の方法 | |
| US11732000B2 (en) | Oxysterols and methods of use thereof | |
| JP6628745B2 (ja) | オキシステロールおよびその使用方法 | |
| JP2021167334A (ja) | オキシステロールおよびその使用方法 | |
| JP2018519329A (ja) | オキシステロールおよびそれらの使用の方法 | |
| RU2850468C2 (ru) | Оксистеролы и способы их применения | |
| HK40051330B (en) | Oxysterols and methods of use thereof | |
| BR122021005567B1 (pt) | Composto oxiesterol, composição farmacêutica e seus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181001 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181001 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190723 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191223 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200305 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200519 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201112 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210202 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20210512 |